Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Antisense technology: an overview and prospectus
Antisense technology is now beginning to deliver on its promise to treat diseases by
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …
targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing …
Nucleic acid drugs: recent progress and future perspectives
X Sun, S Setrerrahmane, C Li, J Hu, H Xu - Signal Transduction and …, 2024 - nature.com
High efficacy, selectivity and cellular targeting of therapeutic agents has been an active area
of investigation for decades. Currently, most clinically approved therapeutics are small …
of investigation for decades. Currently, most clinically approved therapeutics are small …
[HTML][HTML] Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …
[HTML][HTML] Basic, translational and clinical aspects of bronchiectasis in adults
Bronchiectasis is a common progressive respiratory disease with recognisable radiological
abnormalities and a clinical syndrome of cough, sputum production and recurrent respiratory …
abnormalities and a clinical syndrome of cough, sputum production and recurrent respiratory …
MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies
COVID-19 is a highly transmissible disease caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), affects 226 countries and continents, and has resulted in> 6.2 …
coronavirus-2 (SARS-CoV-2), affects 226 countries and continents, and has resulted in> 6.2 …
The challenges and opportunities in the development of MicroRNA therapeutics: a multidisciplinary viewpoint
microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size,
specific targetability, and critical role in disease pathogenesis. However,< 20 miR targeting …
specific targetability, and critical role in disease pathogenesis. However,< 20 miR targeting …
Drug discovery perspectives of antisense oligonucleotides
Y Kim - Biomolecules & therapeutics, 2023 - pmc.ncbi.nlm.nih.gov
The era of innovative RNA therapies using antisense oligonucleotides (ASOs), siRNAs, and
mRNAs is beginning. Since the emergence of the concept of ASOs in 1978, it took more than …
mRNAs is beginning. Since the emergence of the concept of ASOs in 1978, it took more than …
[HTML][HTML] One size does not fit all: the past, present and future of cystic fibrosis causal therapies
Cystic fibrosis (CF) is the most common monogenic disorder, caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene. Over the last 30 years, tremendous …
transmembrane conductance regulator (CFTR) gene. Over the last 30 years, tremendous …
Non-coding RNA-directed therapeutics in lung cancer: delivery technologies and clinical applications
Lung cancer is one of the most aggressive and deadliest health threats. There has been an
increasing interest in non-coding RNA (ncRNA) recently, especially in the areas of …
increasing interest in non-coding RNA (ncRNA) recently, especially in the areas of …
[HTML][HTML] Development of inhalable ATRA-loaded PLGA nanoparticles as host-directed immunotherapy against tuberculosis
Develo** new effective treatment strategies to overcome the rise in multi-drug resistant
tuberculosis cases (MDR-TB) represents a global challenge. A host-directed therapy (HDT) …
tuberculosis cases (MDR-TB) represents a global challenge. A host-directed therapy (HDT) …